BMS's Reblozyl Data Supports Adding Less Severe Patients To Label

 
• By Joseph Haas
Bristol-Myers-Squib_685347493_1200.jpg
BMS and partner Acceleron hope to move Reblozyl into earlier-stage anemia

More from Clinical Trials

More from R&D